<DOC>
	<DOCNO>NCT01596140</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose vemurafenib give combination either everolimus temsirolimus . The safety drug combination also study . Vemurafenib design block BRAF inside cancer cell , mutation involve cancer cell growth . Temsirolimus everolimus design block growth cancer cell , may cause cancer cell die .</brief_summary>
	<brief_title>Vemurafenib Combination With Everolimus Temsirolimus With Advanced Cancer</brief_title>
	<detailed_description>Study Drug Administration : If find eligible take part study , doctor decide whether receive either everolimus temsirolimus You assign dose level vemurafenib base join study . Up 5 dose level vemurafenib test . Up 6 participant enrol dose level . The first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . This continue high tolerable dose vemurafenib find . Study Drug Administration : You take 3 vemurafenib tablet morning 3 tablet evening.You take every day 28-day study cycle . You take vemurafenib combination either 1 tablet everolimus every day cycle receive temsirolimus vein 30-60 minute Days 1 , 8 , 15 , 22 cycle . You receive dose diary record ONLY date time NOT take schedule dose study drug . You bring diary use unused study drug bottle next study visit ( even empty bottle must return ) . Study Visits : At study visit , ask drug may take side effect . On Days 1 15 Cycle 1 Day 1 Cycle 6 : - You physical exam , include measurement vital sign . - Your performance status record . - Blood ( 3 teaspoon ) draw routine test . - You ECG ( Day 15 ) On Day 1 Cycles 2 5 : - You physical exam , include measurement vital sign . - Your performance status record . - Blood ( 3 teaspoon ) draw routine test . - You ECG . - Your skin check . - You CT scan MRI scan check status disease ( Cycle 5 ) . On Day 1 Cycle 3 : - You physical exam , include measurement vital sign . - Your performance status record . - Blood ( 3 teaspoon ) draw routine test . - You ECG . - You CT scan MRI scan check status disease . On Day 1 Cycle 4 : - You physical exam , include measurement vital sign . - Your performance status record . - Blood ( 3 teaspoon ) draw routine test . - You ECG . - You head neck exam check status disease . On Day 1 Cycle 7 : - You physical exam , include measurement vital sign . - Your performance status record . - Blood ( 3 teaspoon ) draw routine test . - You CT scan MRI scan check status disease . - You head neck exam check status disease . On Day 1 Cycles 8 beyond : - You physical exam , include measurement vital sign . - Your performance status record . - Blood ( 3 teaspoon ) draw routine test . After Cycle 7 , every 12 week : - You ECG . - You head neck exam check status disease . - Your skin check . On Day 1 every 2 cycle : - You CT scan MRI scan check status disease . Length Study : You may continue take study drug long doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study complete follow-up . End Study Drug Dosing Visit : Once longer take study drug , study visit . At visit : You ask drug may take side effect . - You physical exam , include measurement vital sign . - Your performance status record . - Blood ( 3 teaspoon ) draw routine test . - You ECG . - You CT scan MRI scan check status disease . - Your skin check . Safety Follow-Up Visit : If leave study reason disease get bad , follow-up visit 28 day last dose . At visit : - You ask drug may take side effect . - You ECG . - Your skin check . - You head neck exam check status disease . Follow-Up : Every 3 month last dose study drug ( 12 month ) contact phone ask new drug may take . This take less 5 minute . This follow may regularly schedule clinic visit . Participant Responsibilities : - Take study drug instruct study staff . - Keep study appointment . If keep appointment , reschedule soon know miss appointment . - Tell doctor study staff side effect , doctor visit , hospitalization may . - Keep study drug safe place , use , away child . It must store room temperature warmer 77 degree F ( 25 degree Celsius ) . - Complete diary instruct - While study , take part research project without approval doctor . This investigational study . Vemurafenib FDA-approved metastatic melanoma . Its use type cancer investigational . Everolimus temsirolimus FDA approve kidney cancer . The combination drug investigational . Up 114 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Confirmation BRAF mutationpositive malignancy require selection patient vemurafenib therapy 2 . Measurable nonmeasurable disease RECIST 1.1 . 3 . Patients advance cancer refractory standard therapy , relapse standard therapy , standard therapy available improves survival least three month . 4 . Patients must least 3 week past receive cytotoxic therapy least 5 halflives previous treatment 3 week , whichever short , biologic therapy . Patients may receive palliative radiotherapy immediately treatment provide target lesion radiate . 5 . ECOG performance status &lt; /= 2 ( Karnofsky &gt; /= 60 % ; Lansky Score &gt; /= 50 ) . 6 . Patients must normal organ marrow function define : absolute neutrophil count &gt; /=1,000/mL ; platelet &gt; /=50,000/mL ; creatinine &lt; 2.0 ; total bilirubin &lt; 2.0 ; ALT ( SGPT ) &lt; /= 3 X ULN ; Exception patient liver metastasis : ALT ( SGPT ) &lt; /= 5 X ULN . 7 . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation , 30 day last dose . 8 . Ability understand willingness sign write informed consent document . 1 . Patients uncontrolled concurrent illness , include limited : ongoing active infection require hospitalization ; psychiatric illness/social situation would limit compliance study requirement . 2 . Exclusion patient creatinine &gt; 2.0 bilirubin &gt; 2.0 . 3 . Pregnant lactating woman . 4 . Patients history bone marrow transplant within previous two year . 5 . Patients know hypersensitivity component drug product . 6 . Patients major surgery within 30 day prior enter study . 7 . Patients baseline QTc &gt; 500 ms. 8 . Patients unable swallow pill .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Vemurafenib</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Afinitor</keyword>
	<keyword>RAD001</keyword>
	<keyword>temsirolimus</keyword>
	<keyword>BRAF gene mutation</keyword>
	<keyword>solid tumor</keyword>
	<keyword>relapse BRAF mutation positive malignant melanoma</keyword>
	<keyword>refractory BRAF mutation positive malignant melanoma</keyword>
</DOC>